Detalhe da pesquisa
1.
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.
Eur J Clin Pharmacol
; 77(10): 1473-1484, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-33969434
2.
Moving Targets: Recent Advances in Lipid-Lowering Therapies
Arterioscler Thromb Vasc Biol
; 39(3): 349-359, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30676072
3.
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Circulation
; 138(13): 1304-1316, 2018 09 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-29735484
4.
Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials.
Curr Opin Cardiol
; 33(3): 269-275, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29561319
5.
How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population.
Diabetologia
; 60(7): 1271-1275, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28409210
6.
Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study.
Eur Heart J
; 37(11): 880-9, 2016 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-26681771
7.
Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study.
J Lipid Res
; 57(4): 697-705, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26828068
8.
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
Circulation
; 141(22): 1829-1831, 2020 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32479195
9.
Carotid arterial wall inflammation in peripheral artery disease is augmented by type 2 diabetes: a cross-sectional study.
BMC Cardiovasc Disord
; 16(1): 237, 2016 11 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27887576
10.
PCSK9 inhibition: the way forward in the treatment of dyslipidemia.
BMC Med
; 13: 258, 2015 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-26456772
11.
Homozygous familial hypercholesterolaemia: light at the end of the tunnel.
Eur Heart J
; 39(14): 1169-1171, 2018 04 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29020270
12.
Systemic wound care: a meta-review of cochrane systematic reviews.
Surg Technol Int
; 24: 99-111, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24700218
13.
Recent failures in antiatherosclerotic drug development: examples from the thyroxin receptor agonist, the secretory phospholipase A2 antagonist, and the acyl coenzyme A: cholesterol acyltransferase inhibitor programs.
Curr Opin Lipidol
; 24(6): 459-66, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24184941
14.
Can we afford not to screen for FH?
Eur Heart J
; 38(23): 1840-1842, 2017 06 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-28444214
15.
Homozygous familial hypercholesterolemia in China: Genetic and clinical characteristics from a real-world, multi-center, cohort study.
J Clin Lipidol
; 16(3): 306-314, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35379578
16.
Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies.
Mayo Clin Proc
; 95(1): 77-89, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31630870
17.
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial.
JAMA Cardiol
; 4(11): 1067-1075, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31553410
18.
Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program.
Future Cardiol
; 14(6): 433-442, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30375244
19.
Inhibiting PCSK9 - biology beyond LDL control.
Nat Rev Endocrinol
; 15(1): 52-62, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30367179
20.
PCSK9 inhibitors in clinical practice: Delivering on the promise?
Atherosclerosis
; 270: 205-210, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29254691